Circulating CHI3L1/YKL-40 in lung cancer: Biomarker potential, analytical challenges, and clinical translation prospects.
A simple blood test for YKL-40 could help doctors track lung cancer progression once standardized testing becomes available.
Omer AB et al. reviewed the biomarker potential of circulating CHI3L1/YKL-40 in lung cancer, discussing analytical challenges and prospects for clinical translation. YKL-40 may serve as an accessible serum biomarker for lung cancer progression monitoring but requires assay standardization before widespread adoption.
What the study was
- Study design
- Review
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Clinica chimica acta
Why it surfaced
Clinically relevant biomarker review for lung cancer; informative but not novel enough to meet HIGH criteria.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.